Navigation Links
Adamas Pharmaceuticals presenta datos clínicos positivos para ADS-5102, un tratamiento para la disquinesia inducida por levodopa, en el Congreso Mundial del Parkinson
Date:10/2/2013

ndo con las restantes actividades de solicitud de nuevo fármaco".

La prueba clínica EASED™ Fase 2/3 se creó para investigar la seguridad y la eficacia de tres niveles de dosis de ADS-5102 administradas una vez por la noche, a la hora de acostarse, para el tratamiento de la LID en la PD. En el estudio participaron 83 sujetos que fueron aleatorizados en una relación de 1:1:1:1 para los cuatro grupos de tratamiento: placebo, 260 mg de ADS-5102, 340 mg de ADS-5102 y 420 mg de ADS-5102. Tanto el nivel de dosis de 340 mg como el de 420 mg de ADS-5102 redujeron considerablemente la LID medida por el cambio en la puntuación total de la Escala Unificada para la Evaluación de la Disquinesia (UDysRS) en ocho semanas frente al placebo, alcanzando el punto final primario del estudio clínico. Es de notar que la reducción en la LID se vio a las dos semanas después de la primera dosis de medicamento en el estudio. En la octava semana, el período de respuesta a los medicamentos sin disquinesia molesta, medido por los diarios de los pacientes, fue de 11.0 horas, 11.5 horas y 12.1 horas para los niveles de dosis de 260 mg, 340 mg y 420 mg, respectivamente, en comparación con 8.0 horas para el placebo. Estos resultados fueron estadísticamente significativos, demostrando un incremento de unas 3 horas sobre el placebo en comparación con los valores de la línea de base.  ADS-5102 también mostró una mejora funcional estadísticamente significativa en la disquinesia evaluada según la parte IV de la MDS-Escala Unificada para la Evaluación de la Enfermedad de Parkinson (MDS-UPDRS), una medida del grado de impacto que la disquinesia tiene en la función diaria del paciente en actividades e interacciones sociales.

El tratamiento con ADS-5102 no dio como resultado un empeoramiento de la PD, según la medición de la puntuación combinada de MDS-UP
'/>"/>

SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
2. Adamas Pharmaceuticals To Report Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia In Parkinsons Disease
3. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
4. Valeant Pharmaceuticals Announces Partnership With National Coalition Against Domestic Violence
5. Ampio Pharmaceuticals subsidiary Luoxis Diagnostics announces positive summary data from study of traumatic brain injury patients and issuance of companys third US patent for its oxidation-reduction potential diagnostic platform
6. Amgen Successfully Completes Onyx Pharmaceuticals Tender Offer
7. Inovio Pharmaceuticals to Participate in Immunotherapy Panel and Present at the 12th Annual BIO Investor Forum
8. Ampio Pharmaceuticals, Inc. Announces Additional Positive Results for Ampion(TM) in Osteoarthritis of the Knee Clinical Trial
9. Immune Pharmaceuticals Announces Focus on Capital Raising and Primary Listing in The United States
10. Industry Landscape Opens Doors for GeoBargain Polydex Pharmaceuticals
11. Prolong Pharmaceuticals Presents Novel Multi-Pronged Approach To Treating Sickle Cell Disease At The SCDAA Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014  SiteOne Therapeutics Inc. ... equity financing. Led by Sears Capital Management and Biobrit ... Joe Zakrzewski , the $1.5 million financing positions SiteOne ... for pain and to further develop its technology platform ... indications. In conjunction with the financing, ...
(Date:9/23/2014)...   COTA, Inc. today announced it has ... A funding round led by Horizon Healthcare Services, Inc. ... big data platform designed by practicing oncologists to deliver ... care in support of healthcare,s new value-based reimbursement model. ... of the COTA platform, hire biostatisticians, outcome analysts, data ...
(Date:9/23/2014)... , Sept. 23, 2014  While proton therapy recently began in the ... Ashya King , another case in the United States ... a young boy who was given just days to live now looks ... Logan Green of Arizona complained of a ... of medical treatments that will conclude Sept. 23, when he completes ...
Breaking Medicine Technology:SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 45-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 25-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 35-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 4
... Pervasis Therapeutics, Inc. today announced that it has ... government,s Qualifying Therapeutic Discovery Project, which provides tax credits ... produce new therapies, reduce long-term health care costs, or ... next 30 years.   Pervasis is a ...
... 4, 2010 The physicians of Westside Medical Associates ... Beverly Hills , California have announced the results of a ... CT scans save lives.  According to Drs. Norman ... Medical Imaging, this study should once and for all settle ...
Cached Medicine Technology:Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project 2Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project 3Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project 4Annual CT Lung Screening Saves Lives 2
(Date:9/23/2014)... first year follow a set of predictable steps ... first words. However, previous research had not addressed ... hearing and deaf infants. Now, University of Missouri ... by infants, ability to hear their own babbling. ... cochlear implants to help correct their hearing soon ...
(Date:9/23/2014)... PITTSBURGH, PA (PRWEB) September 23, 2014 "The ... and infection control," said an inventor from Sacramento, Ca.. "Call ... patient bedding or left hanging on the IV pole out ... patients have the nurse call device whenever they need it, ... CADDY to effectively position the nurse call device within easy ...
(Date:9/23/2014)... CONVENE PATHWAYS TO PREVENTION WORKSHOP: ROLE OF OPIOIDS IN ... , The National Institutes of Health is convening a ... evidence on the long-term effectiveness and potential risks of ... the nation,s top experts in the field of pain ... as key NIH scientists who focus on pain related ...
(Date:9/23/2014)... September 23, 2014 World of Home ... philanthropic support. Most recently, the gym has been raising ... Fitness program. Throughout the year, World of Home Fitness ... charitable causes. , Over the summer, World of Home ... Through their Ageless Fitness program, participants helped feed seniors ...
(Date:9/23/2014)... San Diego, CA (PRWEB) September 23, 2014 ... website daily regarding all the latest information from the ... announced on September 5, that its Private Label Jalapeno ... glass and small stones. Publix Jalapeno Bagels ... in the bakery department. , Taking into consideration ...
Breaking Medicine News(10 mins):Health News:Infant cooing, babbling linked to hearing ability, MU researcher finds 2Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 2Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 3Health News:World of Home Fitness Supports Meals on Wheels 2Health News:Publix Private Label Jalapeno Bagels Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2
... Aug. 31 Endo Pharmaceuticals (Nasdaq: ENDP ) announced today that ... Sept. 10, 2009, at 2:40 p.m. EDT. Alan Levin, Chief Financial Officer ... The presentation will be webcast live and can be accessed from ... , , About Endo , ...
... , , BERWYN, Pa., Aug. 31 ... service multinational clinical research organization (CRO) conducting studies in over 30 ... today announced that on August 25, 2009, it received a letter ... its Form 10-Q for the period ended June 30, 2009, NASDAQ ...
... , , SCOTTSDALE, ... today announced that, at the Company,s 2009 Annual Meeting of Stockholders, ... an overwhelming majority all of the Company,s nominees to the board ... 63,725,589, representing approximately 56% of the 114,007,240 shares outstanding as of ...
... study, blood-thinning drug best for those at highest risk of ... patients, or those with a prior history of stroke, are ... treat atrial fibrillation, a common heart rhythm disorder, a new ... also say the drug is especially beneficial for patients with ...
... Aug. 31 (HealthDay News) -- Walk-in retail clinics staffed by ... study has found. , Writing in the Sept. 1 issue ... Dr. Ateev Mehrotra said that retail clinics -- which are ... and other retail chain stores such as Target and Wal-Mart ...
... patients choose where to get their care based on how ... at Fox Chase Cancer Center have recently documented a growing ... at high volume centers, which are generally located in metropolitan ... a study published in the Journal of Clinical Oncology ...
Cached Medicine News:Health News:Endo Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2009 2Health News:Encorium Receives NASDAQ Deficiency Letter Regarding Stockholders' Equity 2Health News:Encorium Receives NASDAQ Deficiency Letter Regarding Stockholders' Equity 3Health News:Healthcare Trust of America, Inc. Announces Results of 2009 Annual Meeting of Stockholders 2Health News:Healthcare Trust of America, Inc. Announces Results of 2009 Annual Meeting of Stockholders 3Health News:Oldest Heart Patients May Get Most From Warfarin 2Health News:Retail Medical Clinics Offer Quality Care: Study 2Health News:Retail Medical Clinics Offer Quality Care: Study 3Health News:Does the distance a patient has to travel affect where they choose to get their care? 2
... groups of flexible lighting products. The first ... three different sizes 5", 10", and 15" ... the light). These lights are for use ... ,The second group of flexible lights ...
These units, though small, still offer sufficient output to ensure current is fully adjustable from 0 to 70 mA. Instruction manual, ball electrodes, battery and leads with alligator clips are include...
... two groups of flexible lighting products. The ... in three different sizes 5", 10", and ... of the light). These lights are for ... needed., ,The second group of flexible ...
Designed to be used for neuromuscular blockage monitoring. Provides for easy placement over the ulnar nerve on a patient's wrist. Dual element permits non-invasive monitoring using a single electrode...
Medicine Products: